Skip to main content
Breast Cancer
Overall Survival Benefit with Ribociclib plus Endocrine Therapy in Patients with Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer: 4-Year Follow-Up Study of MONALEESA-7
Read More
Breast Cancer
BYLieve Study Results Support the Use of Alpelisib Combined with Fulvestrant for Hormone Receptor–Positive, HER2-Negative, PIK3CA Mutation–Positive Advanced Breast Cancer
Read More
Breast Cancer
PALOMA-3 Trial Shows Benefits to Overall Survival as Measured by Prognostic Indicators
Read More
Breast Cancer, CDK4/6 Inhibitors, Radiation Therapy
Favorable Tolerability Profile of Sequential Radiation Therapy in Patients Receiving CDK4/6 Inhibitors for Metastatic Breast Cancer
Read More
Breast Cancer
Expanded Safety Analysis of the Phase 3b CompLEEment-1 Trial with Ribociclib plus Letrozole in Patients with Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer
Read More
Breast Cancer, CDK4/6 Inhibitors
A Network Meta-Analysis of Treatment-Related Adverse Events of Various CDK4/6 Inhibitors in Metastatic Breast Cancer
Read More
Breast Cancer
Maintenance Therapy with Everolimus plus Aromatase Inhibitors in Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer: Updated Analyses of the Phase 3 Randomized MAIN-A Trial
Read More
Breast Cancer
Patients with Metastatic Breast Cancer and the Use of Chemotherapy During End of Life
Read More
Breast Cancer
In a Real-World Setting, the RIBANNA Study Showed Diverse Population Characteristics Among Patients Who Received Ribociclib Treatment
Read More
Breast Cancer, CDK4/6 Inhibitors
Retrospectively Analyzing the Use of CDK4/6 Inhibitors to Treat Adult Female Patients with Metastatic Breast Cancer
Read More
Page 107 of 199
Results 1061 - 1070 of 1986